This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The content is provided by TotalHealthRD.com, a health information website operated by a Registered Dietitian Nutritionist — not a medical practice or healthcare facility. GLP-1 medications are prescription-only products requiring evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved finished drug products. Individual results vary. Consult your physician before starting, stopping, or changing any prescription medication. Pricing information is current as of May 2026 — visit each program's official website for current pricing and terms. This is a Traffic-first article — no affiliate links are present.
By TotalHealthRD.com Editorial Team
Quick Answer: This comparison evaluates four GLP-1 telehealth programs — Hims & Hers, LifeMD, Novi, and Ro — against five criteria: pricing structure, cancellation terms, pharmacy transparency, insurance support, and ongoing clinical support. No independent product testing was conducted; all information is sourced from each program's published materials and terms documents as of May 2026. These programs are best understood as access vehicles to compounded or FDA-approved GLP-1 medications, not as manufacturers of those medications. The right program depends on whether you have insurance coverage, how important prior authorization support is, how you interpret each program's cancellation terms, and how much transparency you want about who fills your prescription.
How We Evaluated These GLP-1 Telehealth Programs
Four programs were selected for this comparison based on SERP visibility for GLP-1 telehealth search queries, market presence in the compounded and direct-to-consumer GLP-1 space, and relevance to the TotalHealthRD.com audience — women in midlife seeking cash-pay or insurance-supported weight management options. The four programs are: Hims & Hers, LifeMD, Novi, and Ro. They are presented in alphabetical order. This ordering reflects no judgment about program quality.
Each program was evaluated against five dimensions: (1) Pricing structure — what the all-in monthly cost is, whether it includes medication and clinician access, and whether promotional pricing is clearly distinguished from standard pricing. (2) Cancellation terms — what the terms of service actually say about cancellation, minimum commitment periods, and refund eligibility, as distinct from FAQ or marketing language. (3) Pharmacy transparency — whether the program names its pharmacy partner and discloses the compounding pathway (503A vs. 503B). (4) Insurance support — whether the program offers prior authorization assistance for brand-name GLP-1 coverage. (5) Clinical support structure — what ongoing clinician access looks like after the initial prescription is written.
No independent product testing was conducted. Information is sourced from each program's published website, published terms of service and FAQ documents, and verified third-party reporting as of May 2026. This comparison may not reflect pricing or terms changes after that date. The April 30, 2026 FDA proposal to exclude semaglutide and tirzepatide from the 503B Bulks List is a regulatory development affecting all programs offering compounded GLP-1 medications — that context applies to every program in this comparison, not any one of them specifically.
The Comparison Framework: Five Decision Points That Matter
Before the individual program evaluations, a brief note on what each decision point reveals about a program's practical suitability for different patients. Pricing structure matters because GLP-1 therapy is a long-duration commitment — the clinical trial outcomes that established these medications' efficacy were measured at 68-72 weeks. The per-month cost multiplied by 12 is the relevant budgeting figure, not the promotional first-month price. Cancellation terms matter because the gap between marketing language and terms of service language is wide in several programs in this category — knowing what you are actually agreeing to at enrollment prevents disputes. Pharmacy transparency matters because knowing whether your prescription is filled by a 503A-licensed sterile compounding pharmacy with USP 797 accreditation is a safety due-diligence step, especially given the FDA adverse event data on compounded GLP-1 dosing errors. Insurance support matters for patients with commercial insurance that may cover Wegovy or Zepbound with prior authorization — those programs save significantly more over the long term than cash-pay compounded programs. Clinical support structure matters because GLP-1 pharmacotherapy involves dose escalation, side-effect management, and long-term monitoring — programs that hand you a prescription and disappear are not providing the clinical oversight the medication requires.
Hims and Hers
Hims & Hers is one of the largest telehealth platforms in the US and has made GLP-1 weight loss a central offering in recent years. The program initially built its GLP-1 business on compounded semaglutide, and has since added access to brand-name Wegovy through a direct partnership with Novo Nordisk — a positioning shift that reflects the regulatory pressure on compounded GLP-1 supply.
On pricing: Hims & Hers brand-name GLP-1 plans are prepaid and non-refundable, with plan durations of 3-, 6-, 10-, or 12-month options. The compounded options were priced in the $100-$200/month range during the peak of the compounded market; current pricing reflects the regulatory transition. The prepayment structure for brand-name plans means a substantial upfront commitment.
On cancellation terms: plans are prepaid and non-refundable after purchase. The commitment structure is clear — the plan duration purchased is the commitment. On pharmacy transparency: Hims & Hers has not consistently disclosed the specific sterile compounding pharmacy partners for its compounded products in its public-facing materials. On insurance support: Hims & Hers now offers Wegovy access and has infrastructure supporting insurance pathways for brand-name GLP-1s. On clinical support: ongoing clinician messaging is available through the platform's app-based interface. Complaint patterns in third-party reviews center on delays in compounded shipments and pre-paid plan limitations.
LifeMD
LifeMD is a publicly traded telehealth company (NASDAQ: LFMD) that offers both compounded and brand-name GLP-1 options. Its published positioning emphasizes insurance prior authorization support — assistance navigating commercial insurance coverage for branded Wegovy or Zepbound — alongside direct-pay compounded options for patients without coverage.
On pricing: LifeMD's GLP-1 pricing varies based on whether the patient pursues the compounded cash-pay path or the brand-name insurance-supported path. Compounded semaglutide has been priced around $75-$200/month in published materials, varying by plan structure. Brand-name medication cost depends on insurance coverage and co-pay status. On cancellation terms: LifeMD offers GLP-1 services without a multi-month upfront commitment in its standard structure, though specific terms should be verified on the current enrollment page before signing up. On pharmacy transparency: LifeMD has been more forthcoming than some competitors about pharmacy partnership disclosures in its published materials. On insurance support: this is LifeMD's clearest differentiator — the platform has dedicated prior authorization support teams for commercial insurance plans covering GLP-1 medications. For patients with commercial insurance, this is a meaningful operational difference. On clinical support: LifeMD includes metabolic testing and structured follow-up in some plan tiers.
Novi
Novi, operated by Novi International LLC (Sheridan, Wyoming), offers compounded semaglutide and compounded tirzepatide through a telehealth prescribing model. The all-in pricing model — medication, supplies, shipping, clinician support, and coaching bundled together — is Novi's clearest structural differentiator among these four programs.
On pricing: offer-page pricing as of May 2026 is $133/month for compounded semaglutide and $166/month for compounded tirzepatide. These are promotional prices inclusive of all program components. On cancellation terms: this is where Novi requires careful reading. The FAQ describes month-to-month flexibility with no minimum commitment. The Terms of Service describe a three-month upfront commitment with the first three months' fees billed at purchase and non-refundable. These two positions are in direct conflict. The Terms of Service is the legally binding document. Prospective patients should email [email protected] before enrolling to confirm in writing which cancellation terms govern their specific enrollment. On pharmacy transparency: Novi does not publicly name its pharmacy partner(s). The compounding pathway (503A or 503B) is not disclosed. Given the regulatory environment for 503B compounding, this is a gap worth closing directly with Novi's support team. On insurance support: Novi is cash-pay only; the FAQ notes insurance may reimburse for branded alternatives, but Novi does not coordinate that process. On clinical support: named, board-certified providers are listed; unlimited ongoing support is included in the published program. A detailed full review of the Novi program is available at Novi GLP-1 Review 2026.
Ro
Ro (Ro Body Program) is a health technology company that has built a strong reputation for insurance navigation support in the GLP-1 space. Its positioning is oriented toward patients who have commercial insurance and want support with the prior authorization process for brand-name medications like Wegovy or Zepbound, as opposed to defaulting to compounded medications as a first option.
On pricing: brand-name medication cost through Ro depends on insurance coverage; Ro's program fee covers the clinical support and prior authorization work. For patients without insurance or with plans that don't cover GLP-1s, Ro also offers compounded options. On cancellation terms: Ro's program structure varies by enrollment type; current terms should be verified on the enrollment page. On pharmacy transparency: for brand-name medications, Ro uses standard retail pharmacy distribution; for compounded options, pharmacy sourcing should be confirmed directly. On insurance support: Ro is the strongest option in this comparison, with dedicated teams that pursue commercial insurance coverage for brand-name GLP-1 medications. Approval times of 3-10 business days for prior authorizations have been cited in industry reporting, compared to 4-6 weeks for most primary care offices. On clinical support: structured check-ins and ongoing clinical access are included in the program structure.
Side-by-Side: The Five Decision Points
Pricing (all-in monthly, cash-pay compounded): Hims: $100-$200+ range, varies by plan and current regulatory status. LifeMD: approximately $75-$200/month cash-pay, varies by plan. Novi: from $133/month (semaglutide), from $166/month (tirzepatide), all-inclusive. Ro: program fee plus medication cost; primarily structured around brand-name insurance pathways.
Cancellation terms: Hims: prepaid plans are non-refundable after purchase; duration commitment is tied to the plan purchased. LifeMD: no multi-month upfront commitment in standard structure (verify current terms). Novi: FAQ says month-to-month; ToS says three months minimum, billed upfront, non-refundable — confirm with support before enrolling. Ro: varies by enrollment type; verify current terms.
Pharmacy transparency: Hims: compounding pharmacy partner not consistently disclosed publicly. LifeMD: more forthcoming in published materials on pharmacy partnerships. Novi: pharmacy partner not publicly named; compounding pathway not disclosed. Ro: brand-name uses standard retail pharmacy; compounded pharmacy partner should be confirmed directly.
Insurance support: Hims: improving infrastructure for brand-name GLP-1 access. LifeMD: strong prior authorization support. Novi: cash-pay only, no insurance support. Ro: strongest prior authorization support among these four.
Clinical support structure: All four programs include ongoing clinician access in their published models. Depth of structured follow-up varies — Hims is primarily app-based messaging; Ro and LifeMD describe more structured check-in protocols in some tiers; Novi includes unlimited clinician support and coaching in the all-in price.
Which Program for Which Situation
You have commercial insurance and want brand-name GLP-1 coverage: Ro or LifeMD. Both have dedicated prior authorization infrastructure. Ro in particular has built its market identity around this use case. The time investment in the prior authorization process pays off over the 12+ month treatment horizon if your plan covers Wegovy or Zepbound.
You have no insurance coverage for GLP-1 medications and need the most transparent all-in cash-pay price: Novi's published all-in pricing model makes budgeting straightforward — one price covering medication, supplies, shipping, clinician access, and coaching. The caveat is the discrepancy in the cancellation term that must be confirmed before enrolling. LifeMD's cash-pay options are competitive and provide greater pharmacy transparency in its published materials.
You want the widest range of medication options (compounded and brand-name, oral and injectable): Hims & Hers has the broadest current medication menu, including compounded and FDA-approved Wegovy.
You want the most transparency about pharmacy sourcing before enrolling: Of these four programs, LifeMD has been most forthcoming in published materials about pharmacy partnerships. Any program should be able to answer “which pharmacy fills my prescription and what is their accreditation status” before you enroll — it is a reasonable due-diligence question regardless of which platform you choose.
For safety and drug interaction information before starting any of these programs, the GLP-1 Safety Guide 2026 covers the clinical contraindications, drug interactions, and physician consultation triggers that apply to all four. For the regulatory context on compounded versus FDA-approved formulations, see Compounded vs. FDA-Approved GLP-1: What the Evidence Shows. For the underlying medication mechanism, see How GLP-1 Medications Work: A 2026 Research Overview.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The content is provided by TotalHealthRD.com, a health information website operated by a Registered Dietitian Nutritionist — not a medical practice or healthcare facility. GLP-1 medications are prescription-only products requiring evaluation by a licensed healthcare provider. Compounded medications are not FDA-approved finished drug products. All program information reflects published materials as of May 2026; verify current pricing and terms directly with each program before enrolling. This is a Traffic-first article — no affiliate links are present.